New York, New York (PRWEB) June 21, 2014
As Stryker hip lawsuits (http://www.strykerhiprecallclaims.com/) continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes the 2nd anniversary of the Stryker hip recall for Rejuvenate and ABG II Modular-Neck Hip Stems is fast approaching. On July 6, 2012, the U.S. Food & Drug Administration (FDA) announced that Stryker had voluntarily recalled the products after post-market data indicated they were prone to fretting and corrosion at the modular neck junction. When Stryker announced the recall, some 20,000 Rejuvenate and ABG II stems had been sold in the U.S.*
“It is difficult to believe that nearly two years have passed since the Rejuvenate and ABG II stems were pulled from the market. Since then, over two thousand people have filed Stryker hip lawsuits over injuries allegedly caused by these components, and our Firm continues to receive inquiries related to this matter,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who have allegedly been harmed by Rejuvenate and ABG II hip stems.
Stryker Hip Recall
According to the Stryker hip recall notice, fretting and corrosion of the Rejuvenate and ABG II hip stems can place recipients at risk for adverse local tissue reactions, pain and swelling. Stryker has advised all patients fitted with a recalled component to undergo medical screening to ensure it is working properly, even if they have not experienced any symptoms that would indicate otherwise.**
Court documents indicate that more than 2,500 Stryker hip lawsuits have been filed in U.S. courts since the Rejuvenate and ABG II stems were recalled. This includes more than 1,580 claims that are currently pending in a multicounty litigation underway in New Jersey’s Bergen County Superior Court, where Bernstein Liebhard LLP is actively filing lawsuits. According to court records, an Early Mediation Program has been established in this proceeding, and so far all 12 cases selected for Phase I of that program have been resolved. Additional Stryker hip lawsuits are slated to go through the mediation process over the next month. (In Re Stryker Rejuvenate Hip Stem and the ABG II Modular Hip Stem Litigation, No. 296)
In addition to the cases filed in New Jersey, at least 970 Stryker hip lawsuits are pending in a federal multidistrict litigation underway in U.S. District Court, District of Minnesota. (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, No. 244)
Rejuvenate and ABG II hip stem recipients may be eligible for compensation if they allegedly experienced metallosis, osteolysis, premature device failure, or other complications related to the Stryker hip recall. To find out more about filing a Stryker hip lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
*palmbeachpost.com/news/lifestyles/health/artificial-hips-corrode-poisoning-some-patients-lo/nT7jf/, Palm Beach Post, January 2013
**fda.gov/safety/recalls/ucm311043.htm, FDA, July 6, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP